Table 2 |
||||||||
| Health outcomes among HCV patients and controls | ||||||||
| HCV group | Unmatched controls | Matched controls | ||||||
| (n = 286) | (n = 56,880) | (n = 286) | ||||||
| Mean | SD | Mean | SD | p-value* | Mean | SD | p-value† | |
| Work impairment | ||||||||
| Absenteeism | 7.78% | 19.16% | 5.44% | 19.20% | <.001 | 5.45% | 20.34% | .010 |
| Presenteeism | 26.27% | 27.58% | 15.83% | 22.79% | <.001 | 14.45% | 21.58% | <.001 |
| Overall work impairment | 30.45% | 31.42% | 19.39% | 27.70% | <.001 | 18.30% | 27.47% | <.001 |
| Activity impairment | 34.37% | 30.60% | 24.38% | 28.16% | <.001 | 28.46% | 30.57% | .011 |
| Healthcare use | ||||||||
| Annual physician visits | 19.80 | 23.93 | 10.66 | 14.64 | <.001 | 13.26 | 19.21 | <.001 |
| Annual ER visits | 0.68 | 2.11 | 0.38 | 1.90 | .006 | 0.39 | 1.19 | .330 |
| Annual hospitalizations | 0.52 | 1.59 | 0.26 | 2.14 | <.001 | 0.27 | 0.98 | .073 |
| Quality of life (SF-12v2) | ||||||||
| MCS | 44.17 | 9.85 | 46.58 | 10.59 | <.001 | 46.36 | 10.79 | .012 |
| PCS | 43.61 | 10.14 | 48.67 | 9.75 | <.001 | 46.09 | 10.33 | .004 |
| Health utility | 0.67 | 0.12 | 0.73 | 0.13 | <.001 | 0.71 | 0.15 | .001 |
Comparisons of work impairment include only the employed subsamples: 138 HCV patients, 32,179 non-HCV, and 134 matched controls.
*Indicates the significance comparing the HCV group with the unmatched control group.
†Indicates the significance comparing the HCV group with the matched control group.
Vietri et al. BMC Gastroenterology 2013 13:16 doi:10.1186/1471-230X-13-16
